Enzon Pharmaceuticals Inc. (ENZN): Suspending clinical work and selling ass...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Re: None

Monday, 12/17/2012 2:38:33 PM

Monday, December 17, 2012 2:38:33 PM

Suspending clinical work and selling assets or itself: $4.72

Keep Last Read

Replies (1) Next 10 Prev Next

Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/29/2024 08:40:58 PM
Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 07/11/2024 09:01:02 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:05:28 PM
Form 8-A12G/A - Registration of securities [Section 12(g)]: [Amend] • Edgar (US Regulatory) • 05/22/2024 08:11:13 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:05:33 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:07:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:05:44 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:10 PM

InvestorsHub NewsWire

Only $200 per official company press release!